Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27387795 | 0.98 | CYP1A2 (0.62) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL6960124 | 0.95 | SMN1; SMN2 (0.63) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL8380683 | 0.93 | SMN1; SMN2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL151854 | 0.93 | SMN1; SMN2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL8379316 | 0.93 | SMN1; SMN2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL8380782 | 0.93 | SMN1; SMN2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL9874977 | 0.93 | SMN1; SMN2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL5182886 | 0.90 | KMT2A (0.75) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL27979508 | 0.90 | MEN1 (0.61) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL7338840 | 0.89 | ALDH1A1 (0.61) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101544579-B | Use and preparation method of 4-(-2-acetoxybenzoyl)aminobutyric acid and ester derivative thereof | UNIV LANZHOU | 2013-05-22 | — | — | CN | claimed |
| CN-101544579-A | Use and preparation method of 4-(-2-acetoxybenzoyl)aminobutyric acid and ester derivative thereof | UNIV LANZHOU | 2009-09-30 | — | — | CN | claimed |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20230098847-A1 | QUATERNARY HETEROATOM CONTAINING COMPOUNDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-03-30 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-11390585-B2 | Quaternary heteroatom containing compounds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-19 | — | — | US | disclosed |
| US-11333974-B2 | Onium salt, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| CN-110003172-B | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | 同步制药公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022039199-A1 | POLY[IMINO(1-OXO-1,4-BUTANEDIYL)] COPOLYMER, RESIN COMPOSITION OF SAID COPOLYMER, AND RESIN MOLDED BODY | 株式会社クラレ | 2022-02-24 | — | — | WO | disclosed |
| EP-0296979-B1 | 1-BENZOYL-2-OXO-5-ALKOXY-PYRROLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PREPARATIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1991-12-04 | — | — | EP | disclosed |
| EP-0317588-B1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 1991-08-07 | — | — | EP | disclosed |
| US-4985428-A | Isoxazoles with nootropic activity | ZAMBON GROUP S.P.A. (IT) | 1991-01-15 | — | — | US | disclosed |
| EP-0317588-A1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY. | ZAMBON SPA (IT) | 1989-05-31 | — | — | EP | disclosed |
| WO-1988009330-A1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1988-12-01 | — | — | WO | disclosed |
| US-4710573-A | PSYCHOLOGICAL DISORDERS | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0110575-A1 | 1-Aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters | WARNER-LAMBERT COMPANY (US) | 1984-06-13 | — | — | EP | disclosed |
| EP-0005143-B1 | 1-BENZOYL-2-PYRROLIDINONE DERIVATIVE, PROCESSES FOR ITS PREPARATION AND MEDICAMENTS CONTAINING IT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-07-14 | — | — | EP | disclosed |
| EP-0005143-A1 | 1-Benzoyl-2-pyrrolidinone derivative, processes for its preparation and medicaments containing it | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11333974-B2 | Onium salt, chemically amplified resist composition, and patterning process | ARF5, EIF2B3, KAT5 | CYP1A2 3975/4885CYP2D6 3744/4885CYP2C9 3373/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CYP1A2 227/4885CYP2D6 664/4885CYP2C9 242/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | CYP1A2 256/4885CYP2D6 80/4885CYP2C9 164/4885 |
| US-11390585-B2 | Quaternary heteroatom containing compounds | SDHA, NQO1, SDHB | CYP1A2 26/4885CYP2D6 19/4885CYP2C9 103/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CYP1A2 227/4885CYP2D6 664/4885CYP2C9 242/4885 |
| US-20230098847-A1 | QUATERNARY HETEROATOM CONTAINING COMPOUNDS | SDHA, NQO1, SDHB | CYP1A2 26/4885CYP2D6 19/4885CYP2C9 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.